A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma

NCT07333469 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor and Lymphoma

Interventions

DRUG: HX111 for injection

Sponsor

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.